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Background:Loss of CRTC2 improves insulin sensitivity, but it is unknown if chronicCRTC2 activity causes hepatic insulin
resistance.
Results: Liver expression of constitutively active CRTC2 increased hepatic glucose production, despite compensatory increases
in FOXO1 phosphorylation.
Conclusion: Persistent increases in CRTC2 activation promote hepatic insulin resistance.
Significance: Disrupting CREB signaling in liver could provide therapeutic benefit against insulin resistance.
Under fasting conditions, increases in circulating concentra-
tions of glucagon maintain glucose homeostasis via the induc-
tion of hepatic gluconeogenesis. Triggering of the cAMP path-
way in hepatocytes stimulates the gluconeogenic program via
the PKA-mediated phosphorylation of CREB and dephosphor-
ylation of the cAMP-regulated CREB coactivators CRTC2 and
CRTC3. In parallel, decreases in circulating insulin also increase
gluconeogenic gene expression via the de-phosphorylation and
activation of the forkhead transcription factor FOXO1. Hepatic
gluconeogenesis is increased in insulin resistance where it con-
tributes to the attendant hyperglycemia.Whether selective acti-
vation of the hepatic CREB/CRTC pathway is sufficient to trig-
ger metabolic changes in other tissues is unclear, however.
Modest hepatic expression of a phosphorylation-defective
and therefore constitutively active CRTC2S171,275A protein
increased gluconeogenic gene expression under fasting as well
as feeding conditions. Circulating glucose concentrations were
constitutively elevated in CRTC2S171,275A-expressing mice,
leading to compensatory increases in circulating insulin con-
centrations that enhance FOXO1 phosphorylation. Despite
accompanying decreases in FOXO1 activity, hepatic gluconeo-
genic gene expression remained elevated in CRTC2S171,275A
mice, demonstrating that chronic increases inCRTC2activity in
the liver are indeed sufficient to promote hepatic insulin resis-
tance and to disrupt glucose homeostasis.
In unaffected and appropriately regulated systems, blood
glucose levels remain remarkably constant, despite alternating
periods of caloric abundance and scarcity. This level of control
is preserved by balancing hepatic glucose production (gluco-
neogenesis and glycogenolysis) during fasting with the glucose
uptake into peripheral tissues during feeding. The transition
from a high-risk state to type 2 diabetes is marked by insulin
resistance, and an inability for insulin to inhibit hepatic gluco-
neogenesis, resulting in elevated fasting blood glucose (1–4).
Under fasting conditions, increases in glucagon upregulate
the gluconeogenic program by triggering the cAMP pathway
(5) and stimulating the protein kinase A (PKA)2-mediated
phosphorylation of cAMP response element-binding protein
(CREB). Serine 133 phosphorylation of CREB in turn promotes
recruitment of the histone acetyltransferase paralogs CREB-
binding protein (CBP) and P300 (6, 7).
Superimposed on effects of the CREB:CBP pathway, cAMP
also stimulates hepatic gene expression in the liver via the
induction of the cAMP-regulatedCREBCoactivators (CRTCs).
Under basal conditions, CRTCs are phosphorylated by salt-in-
ducible kinases (SIKs) and sequestered in the cytoplasm by
association with 14-3-3 proteins (8). Triggering of the cAMP
pathway promotes the inhibitory phosphorylation of salt
inducible kinases (SIKs) by PKA, leading to the dephosphory-
lation and translocation of CRTCs to the nucleus, where they
associate with relevant target genes via an interaction with
CREB (8–13).
The importance of the CREB:CRTC pathway in hepatic glu-
coneogenesis is supported by studies in which acute RNAi-me-
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diated knockdown of CRTC2 in liver decreases gluconeogenic
gene expression aswell as circulating glucose concentrations (9,
14). Cultured hepatocytes from CRTC2 knock-out mice also
exhibit decreases in glucose production (12, 15), although these
effects are more modest due to compensation by CRTC3 (16).
Recognizing the importance of theCREB/CRTC2pathway in
the fasting adaptation, we wondered whether modest expres-
sion of an active form of CRTC2 in the liver would be sufficient
to increase hepatic gluconeogenesis and promote insulin resis-
tance in peripheral tissues.
We found that selective expression of a constitutively active
form of CRTC2 in liver for a period of up to 5 weeks increases
the set point for circulating concentrations of glucose. This
stable rise in blood glucose levels promotes compensatory
increases in pancreatic islet mass and insulin secretion. The
results point to an important role for hepatic CRTC2 in glucose
homeostasis and in the development of hepatic insulin
resistance.
Experimental Procedures
Adeno-associated Viruses (AAV) Strains and Propagation—
Viruses were derived from pENN AAV TBG PI (an adeno-as-
sociated virus, serotype 8with aTBGpromoter), a generous gift
from Dr. Morris Birnbaum at the University of Pennsylvania.
Briefly, pENNAAVTBG PI was digested with enzymes Acc65I
and SalI (New England Biolabs, Danvers, MA; #R0599 and
#R0138). Meanwhile, a pcDNA3 construct expressing a FLAG-
tagged mouse CRTC2 with mutations S171A and S275A was
amplified by PCR (primers: GCCGGTACCATGACCATG-
GATTACAAGGAT, and GCCGTCGACTAGGTGACAC-
TATAGAATAGG) and then digested with Acc65I and SalI.
The digested pENN AAV TBG PI was ligated with the
FLAG.CRTC2AA PCR fragment and transformed in recombi-
nation-deficient Escherichia coli SURE cells (Agilent, Santa
Clara, CA; #200238).
The resulting vectors (pENN AAV TBG PI and pENN AAV
TBG PI CRTC2AA) were amplified in the Salk Institute Gene
Transfer Targeting and Therapeutics Core. The amplified
viruses are hereafter referred to as AAV.Empty and
AAV.CRTC2AA.
Animals—Mice were housed in colony cages in a temper-
ature controlled environment under a 12 h light/dark cycle
with free access to water and a standard Chow diet (Lab Diet
5001). ChIP studies were performed using 8–10-week-old
C57BL/6J mice from Jackson Laboratories (Bar Harbor, ME;
000664). Unless noted, other studies were performed
using 8–12-week-old B6(Cg)-Tyrc-2J/J mice from Jackson
Laboratories (000058). CRE-Luciferase mice were de-
scribed previously (17).
Mice received daily IP injections of 75 mg streptozotocin
(STZ)/kg body weight in a sodium citrate buffer for three con-
secutive days; controls receive buffer-only injections. Experi-
ments were performed after 14 days after the initial injection.
Mice were injected retro-orbitally at 8–10 weeks with 1011
genomic copies (gc) of AAV.Empty or AAV.CRTC2AA virus as
described (18, 19). All mouse experiments were performed in
accordance with the Salk Institute Institutional Animal Care
and Use Committee.
Mouse Genotyping—Mouse genotypes for CRE-Luciferase
were determined on tail biopsies using real-time PCRwith spe-
cific probes designed for luciferase (Transnetyx, Cordova, TN).
In Vivo Analysis—Pyruvate tolerance was tested in 16-hour
fasted conscious mice after a baseline tail blood glucose mea-
surement, with an intraperitoneal injection of sodium pyruvate
(2 g/kg body weight) followed by tail blood glucose measure-
ments every 15–30 min for 2 h (12).
Whole body insulin sensitivity was measured using the insu-
lin tolerance test (ITT). For this, an intraperitoneal injection of
1 unit of insulin (Humulin-R, Eli Lilly, Indianapolis, IN)/kg
body weight was administered followed by tail blood glucose
measurements every 15 min for 1 h. Muscle and adipose tissue
specimens for determination of Akt phosphorylation (as amea-
sure of insulin action),micewere fasted for 4 h and then admin-
istered an intraperitoneal injection of 1 unit of insulin/kg body
weight as above, and sacrificed 10 min postinjection.
For determination of fasting blood glucose levels, mice were
fasted overnight for 16 h with free access to water. Refed blood
glucose values were determined after 4 h of free access to food.
Glucose tolerance was measured by an intraperitoneal glucose
tolerance test (IPGTT). Glucose (1 g/kg, ip) was administered
followed by tail blood glucose measurements every 30 min for
two hours. Continuous glucose monitoring was performed as
previously described (20). Briefly, the sensor (Dexcom7 system,
Dexcom, San Diego, CA) was inserted under the skin in anes-
thetizedmice and calibrated twice daily based on blood glucose
values determined with a LifeScan One Touch Ultra glucom-
eter (Chesterbrook, PA).
For in vivo imaging of whole body luciferase activity, fasted
and fed CRE-luciferase mice were anesthetized, treated with
D-luciferin (150 mg/kg, IP) and underwent intra-vital imaging
in an IVIS-100 instrument (Caliper Life Sciences) as previously
described (17).
Tail blood glucose values were determined using a LifeScan
One Touch Ultra glucometer. Serum insulin levels were mea-
sured using the Crystal Chem Ultra Sensitive Mouse Insulin
ELISA (Downers Grove, IL; #90080).
Cell Culture and in Vitro Analysis—Primary hepatocytes
were derived from B6(Cg)-Tyrc-2J/J or CRE-Luc mice as previ-
ously described (18, 21). Hepatocytes expressing AAV.Empty
or AAV.CRTC2AA were harvested from 8–10-week-old mice
infected 3 days previously with AAV, andmaintained in serum-
free Medium 199 (Corning, Manassas, VA; #10-060). Hepato-
cytes were either stimulatedwith glucagon (100 nmol/liter, Sig-
ma-Aldrich #G2044) or PBS as a negative control.
Gene Expression Analysis—Total cellular RNA from whole
tissue or from primary hepatocytes was extracted using the
RNeasy kit (Qiagen,Valencia, CA; #74104), and cDNAwas gen-
erated using the iScript select system (Bio-Rad #170-8840).
cDNA was quantified via the LightCycler 480 instrument and
2 SYBR Green (Roche, Indianapolis, IA). Gene expression
data are presented relative to parallel measured expression of
housekeeping cDNA, for example RPL32 (L32).
ProteinAnalysis—Total protein fromwhole tissue or primary
hepatocytes was extracted in RIPA buffer (50 mM TRIS pH 7.5;
150 mM sodium chloride; 1 mM EDTA; 50 mM sodium fluoride;
5 mM sodium pyrophosphate; 10 mM -glycerophosphate; 1%
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Nonidet P-40) containing 1 mM sodium orthovanadate; 1 mM
dithiothreitol; 2 mM phenylmethanesulfonyl fluoride; 0.25%
DOC (sodium deoxycholate); and 0.1% sodium dodecyl sulfate
fromSigma. Proteinswere quantified using theBio-RadProtein
Assay Kit and separated using SDS-PAGE.
Immunoprecipitation—To 1 mg of tissue lysates (1 g/l)
was added 40l of pre-cleared FLAG-M2monoclonal antibody
beads (Sigma #F3165); samples were incubated with rotation
overnight at 4 °C. The supernatant was removed, and beads
were washed five times with lysis buffer, eluted with 2 SDS
loading buffer and analyzed via Western blot.
ChIP Assays—Livers were excised and immediately cross-
linked in 1% formaldehyde while being shredded. Excessive
formaldehyde was inactivated with glycine after 10 min of
cross-linking. Using a hypotonic lysis buffer, nuclei were iso-
lated and homogenized with a Dounce homogenizer. Resulting
chromatin was sonicated 8 times for 10 s at 50% output, pre-
cleared and incubated with the indicated antibodies overnight
in the presence of phosphatase, protease, andHDAC inhibitors.
Precipitated chromatin was purified, quantified by PCR (Light-
cycler 480; Roche), and presented as a percentage of input chro-
matin as previously described (16).
Antibodies and Western Blots—Antibodies used for immu-
noblotting and immunofluorescence were: FLAG-M2 (1:1000,
Sigma #F1804), glucagon (1:500, Sigma #G2645), histone H3
(Abcam#ab1791), Hsp90 (1:3000, SCBt #33755), insulin (1:500,
Xymed #180067), pLKB1 (1:1000, Cell Signaling Technology
#C6783), pFOXO1 Ser-256 (1:1000, Cell Signaling Technology
#9461). For CRTC2 (1:5000), CREB (1:5000), and pCREB
(1:5000), rabbit polyclonal antibodies were raised against
respective antigens (Salk Institute). For all Western blots, sec-
ondary antisera were HRP-conjugated goat anti rabbit IgGs
(1:5000, Bio-Rad #170-6515). Following SDS-Page, proteins
were transferred to PVDF membranes (Millipore, Billerica,
MA; #IPVH00010), blocked with 5% milk TBS-T followed by
incubation with primary and secondary antisera. Antibody
binding was visualized by HyGlo ECL (Denville, South Plain-
field, NJ; #E2500).
Immunofluorescence—Live hepatocytes were plated in glass
chamber slides (BD #354114), and treated as indicated. Slides
were then fixed for 10min in 4% paraformaldehyde in PBS, and
blocked for 30 min [PBS with 1% donkey serum (JAX #017–
000-001) and 1% BSA (Millipore #81-066-4)]. Primary antibod-
ies were incubated overnight in PBS, and secondary antibodies
linked with Alexa-Fluor-488 (donkey antigoat) or -568 (goat
antiguinea pig and donkey antirabbit) (Life Technologies) were
incubated for 2 h and sections were counterstained with DAPI
(1:500, Invitrogen #D3571). Slideswere thenmountedwith 70%
glycerol and PBS, and images taken using a Confocal Zeiss 780.
Tissues were dissected frommice and fixed in Z-Fix for 4 h, and
then sectioned in 5–10 micron slices. Slides were deparaf-
finized and rehydrated, and antigen retrieval via citrate
unmasking by boiling slides in 10mM sodium citrate buffer, pH
6, and left at sub-boiling temperatures for 10 min, and cooled
for 30min. Slides were blocked in blocking buffer (PBS with 1%
donkey serum and 1%BSA), and then incubated overnight with
primary antibodies; followed by fluorescent secondary antibod-
ies for 1 h, and counterstained DAPI. Sections were mounted
with 70% glycerol and analyzed as above.
Islet Quantification—A single investigator (MFH) was
blinded to viral infection for each sample and carried out his-
tological assessment of islets. An average of 17 islets per animal
was analyzed.-cell area (percent of islet area occupied by insu-
lin positive immunoreactivity) was computed using Image Pro
Plus (Media Cybernetics, Bethesda, MD) by determining the
insulin-positive areas within each islet cross-section (22), and
similar calculationswere performed for cell area by determin-
ing the glucagon-positive areas within the islet.
Statistical Analysis—Data are presented as mean S.E. Sta-
tistical differences for one factor between two groups were
determined by use of an unpaired Student’s t test. p values of
0.05 were considered to be statistically significant.
Results
Acute Loss of Insulin Signaling Up-regulates CREB and
CRTC2Activities—CREB andCRTC2 are activated during fast-
ing where they stimulate gluconeogenic gene expression fol-
lowing their recruitment to the promoter (Fig. 1). The CREB/
CRTC2 pathway is inactivated during refeeding, leading to
dismissal of CRTC2 from gluconeogenic promoters. We used
the  cell toxin streptozotocin (STZ) to test the importance of
insulin in regulating hepatic CREB/CRTC2 activity. Amounts
of phosphorylated CREB were comparable between WT and
STZ mice during fasting. By contrast with the refeeding-asso-
ciated decrease in phospho-CREB amounts in controls, how-
ever, hepatic CREB phosphorylation remained elevated in STZ
mice (Fig. 1a). Correspondingly, CRTC2 occupancy over glu-
coneogenic promoters was constitutively increased in STZ
mice; and hepatic PCK1 andG6PasemRNA amounts were also
up-regulated (Fig. 1, b and c). These results demonstrate the
importance of circulating insulin in attenuating CREB and
CRTC2 activities during feeding.
CRTC2Activation Triggers Down-regulation of FOXO1—We
wonderedwhether constitutive activation of theCREBpathway
in liver is sufficient to stimulate the gluconeogenic program.
Based on the ability for adeno-associated viruses (AAVs) to be
stably maintained as extra-chromosomal plasmids in infected
cells, we prepared adeno-associated virus serotype 8 containing
a Flag epitope-tagged CRTC2 cDNA with Serine-Alanine sub-
stitutions at inhibitory (Ser-171, Ser-275) sites. Mice were
injected retro-orbitally with adeno-associated viruses express-
ing CRTC2S171, 275A (denoted AAV.CRTC2AA) or control
virus (AAV.Empty) and followed thereafter for 36 days. Total
hepatic CRTC2 protein amounts were increased by 35% in
hepatocytes from AAV.CRTC2AA mice relative to controls
(Fig. 3a). We detected AAV-encoded CRTC2 only in liver, and
not in quadriceps muscles, white adipose tissue, or brown adi-
pose tissue (Fig. 2a).
To evaluate effects of the CRTC2S171,275AA protein on
hepatic CREB activity, we used transgenic mice expressing a
CRE-Luciferase reporter (17). CREB reporter activity was
robustly increased in AAV.CRTC2AAmice relative to controls
under fasting as well as refed conditions, when hepatic CREB
activity is otherwise downregulated (p 0.05, Fig. 2, b and c).
Activation of CRTC2 Causes Hepatic Insulin Resistance
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Supporting the notion that CREB activity is increased in ani-
mals expressing constitutively active CRTC2, mRNA amounts
for G6Pase expression were higher in AAV.CRTC2AA com-
pared with controls under fasting conditions (Fig. 2d). mRNA
amounts for PCK1 and G6Pase were also up-regulated under
fed conditions in AAV.CRTC2AA compared with control mice
(Fig. 2d, demonstrating that induction of the CREB pathway in
liver is indeed sufficient to stimulate the gluconeogenic pro-
gram. As a result, feeding-associated suppression of PCK1
expression was significantly blunted in livers of AAV.
CRTC2AAmice (49% reduction) compared with controls (74%
reduction; Fig. 2d).
We considered that overexpression of active CRTC2 could
trigger compensatory down-regulation of the forkhead tran-
scription factor FOXO1. Indeed, amounts of Ser-256 phosphor-
ylated and therefore inactive FOXO1 were substantially
increased in livers of ad libitum fed AAV.CRTC2AAmice (Fig.
2e). Despite these increases, FOXO1 phosphorylation was not
sufficient to block CREB/CRTC2 activities.
Constitutive Nuclear Localization of Phosphorylation-defec-
tive CRTC2—In keeping with results in liver, CRTC2 mRNA
amounts were increased nearly 2-fold in AAV.CRTC2AA
hepatocytes (Fig. 3a). Under basal conditions, protein amounts
for dephosphorylated (active; lower band on immunoblot)
CRTC2 were increased by 67% in AAV.CRTC2AA compared
with control (Fig. 3a).
CRTC2 contains a number of phosphorylation sites in addi-
tion to Ser-171 and -275 that also contribute to its mobility (8,
10, 23). We performed immuno-cytochemical studies to visu-
alize differences in nuclear accumulation between control and
CRTC2AA expressing cells. Endogenous CRTC2was primarily
localized to the cytoplasm in the basal state; it shuttled to the
nucleus in response to glucagon. By contrast, overexpressed
CRTC2AA appeared nuclear under both basal and glucagon-
stimulated conditions (Fig. 3b). These results suggest that
AAV-encoded CRTC2AA is primarily expressed in hepato-
cytes, where it is constitutively nuclear-localized. Indeed,
mRNA amounts for gluconeogenic genes (PCK1 and G6Pase)
were up-regulated under basal conditions in hepatocytes from
AAV-CRTC2AA mice. Exposure to glucagon further aug-
mented PCK1 (p 0.05) andG6Pase (p 0.058) expression to
a greater extent inAAV.CRTC2AAhepatocytes comparedwith
controls (Fig. 3c).
Altered Glucose Set Point in Mice Expressing Constitutively
Active CRTC2—Having seen that gluconeogenic gene expres-
sion is increased in isolated hepatocytes as well as livers of mice
expressing the phosphorylation-defective CRTC2 polypeptide,
we examinedwhether circulating blood glucose concentrations
are correspondingly altered. Supporting this notion,
AAV.CRTC2AA expressing mice had higher fasting blood glu-
cose relative to control animals, under both short-term and
overnight fasting conditions over a 5-week period (Fig. 4, a and
FIGURE1.HepaticCREBandCRTC2areactiveunder fastingconditions.a, immunoblot showinghepaticCREB (phosphorylatedand total) under fastingand
refed conditions in STZ treated and control mice. b, relative expression of PCK1 and G6Pase in livers of fasted and refed STZ and control animals. Expression
levels are normalized to L32 and expressed as fold change to control fastedmice, n 3. c, ChIP assay of CRTC2 over PCK1 and G6Pase promoters in livers from
STZ or control mice under fasted and refed conditions; ChIP signals are normalized to total input.
Activation of CRTC2 Causes Hepatic Insulin Resistance
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b). Notably, ad libitum fed blood glucose concentrations were
also increased in AAV.CRTC2AA mice (Fig. 4b).
To determine whether these differences were due to
increases in hepatic gluconeogenesis, we performed a pyruvate
tolerance test. Although glucose output from pyruvate was
increased in the AAV.CRTC2AA animals, this difference
appears to reflect primarily an increase in fasting blood glucose
levels, rather than a change in hepatic gluconeogenesis (Fig. 4c).
Glucose clearance appeared comparable between AAV.
CRTC2AA and control mice by intraperitoneal glucose toler-
ance testing. In keeping with results from pyruvate tolerance
testing, the incremental area under the curve was comparable
between both groups suggesting that the differences in circu-
lating glucose concentration is primarily driven by the initial
elevation in fasting blood glucose levels (Fig. 4d). Indeed,
AAV.CRTC2AA mice had a persistent and fixed elevation
in blood glucose levels by continuous glucose monitoring
throughout an entire light-dark cycle (Fig. 4e), pointing to a
change in the set point for circulating glucose concentrations.
Hepatic Insulin Resistance and Steatosis in Mice Expressing
Constitutively Active CRTC2—Weperformed insulin tolerance
testing to determine whether the elevations in fed and fasted
glucose levels in AAV.CRTC2AA mice were associated with
insulin resistance. Following insulin administration, blood
glucose concentrations decreased in control animals but
they remained elevated in AAV.CRTC2AA mice, demon-
FIGURE 2.Modest overexpression of a phosphorylation-defective CRTC2 polypeptide in liver stimulates gluconeogenic gene expression. a, immuno-
blot showing CRTC2 protein amounts recovered from extracts of different tissues immunoprecipitation of FLAG epitope. Tissues were collected from mice
infected with AAV.Empty or AAV.CRTC2AA (FLAG-tagged) viruses. b, representative live image of CRE-Luciferase reporter mice infected with AAV.Empty or
AAV.CRTC2AA after 3 h of refeeding. c, quantification of hepatic CRE-luciferase expression in mice fasted overnight and refed for 3 h. Bars indicate upper and
lower quartiles, indicates mean, and error bars indicate minimum andmaximum values, n 5–6. d, relative expression of PCK1 and G6Pase genes in livers
of fasted and fedmice infectedwithAAV.EmptyorAAV.CRTC2AAvirus. Expression levels arenormalized to L32 andexpressedas fold change to fedAAV. Empty
mice (set to 1), n 5. (*, p 0.05; **, p 0.005; ***, p 0.0005 compared with AAV.Empty mice; #, p 0.05; ##, p 0.005; ###, p 0.0005 compared with
fasted/fed of same viral infection; data shown asmean S.E.). e, phospho-FOXO1 levels of in livers of fed animals 36 days post viral infection, quantification of
blots shown to right. Biological replicates shown.
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strating that AAV.CRTC2AA mice are indeed insulin resist-
ant (Fig. 5a).
To determine if the observed increase in insulin resistance is
also transmitted to peripheral tissues (muscle and fat), wemea-
sured effects of insulin on AKT phosphorylation in epididymal
white adipose tissue (WAT) and quadriceps muscles.
Phospho(Ser-473)AKT amounts appeared comparable
between control and AAV.CRTC2AAmice under basal condi-
tions and following insulin injection (Fig. 5b), indicating that
the effects of CRTC2AAare likely confined to the liver. In keep-
ing with the presence of hepatic insulin resistance, CRTC2AA
mice had morphological evidence of hepatic steatosis (Fig. 5c).
Hepatic triglycerides also appeared higher under under ad libi-
tum fed conditions, although they did not reach the level of
statistical significance (p 0.06, Fig. 5d).
Hepatic insulin resistance is often associated with increased
serum insulin levels under ad libitum conditions (Fig. 6a) and
compensatory increases in islet cell mass. Indeed, -cell area
was increased 36% in AAV.CRTC2AA mice, whereas -cell
area was unchanged (Fig. 6, b and c). This increase was associ-
ated with an overall increase in islet area, and was due to the
increase in islet cell number rather than cell size (Fig. 6d). Col-
lectively, these results indicate that constitutive activation of
the CREB pathway in liver is sufficient to promote insulin resis-
tance and compensatory islet hyperplasia.
Discussion
Insulin resistance is a major risk factor for the development
of type 2 diabetes, which is characterized by an inability for
insulin to promote glucose uptake into muscle and to inhibit
glucose production by the liver. Hepatic glucose output is ele-
vated in type 2 diabetes, where it contributes to a number of
complications including heart disease and peripheral neuropa-
thy. We found that persistent activation of the CREB pathway
in liver promotes hepatic steatosis and stimulates constitutive
increases in blood glucose concentrations.
Hepatic expression of AAV-encoded CRTC2AA triggered
substantial increases in the activity of a hepatic CREB reporter
FIGURE 3. Effect of phosphorylation-defective CRTC2 on gluconeogenic gene expression in isolated hepatocytes. a, immunoblot of hepatocytes iso-
lated from mice infected with AAV.Empty or AAV.CRTC2AA viruses. Cells were exposed to glucagon (100 nM) or PBS for 1 h. Amounts of dephosphorylated
CRTC2 quantified below. (*, p 0.05; data shown asmean S.E.) b, immunofluorescence images of hepatocytes isolated frommice infectedwith AAV.Empty
or AAV.CRTC2AA (as in a). c, effect of glucagon or PBS (1 h) on gluconeogenic gene expression in hepatocytes isolated frommice previously infectedwith AAV.
Empty or AAV.CRTC2AA. All expression values are normalized to L32 and then expressed as fold changewhere hepatocytes fromAAV. Emptymice treatedwith
PBS are set to 1, n 3. (*, p 0.05; ***, p 0.0005 compared with AAV. Empty of same treatment; data shown as mean S.E.)
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that contains eight tandem CREB binding sites (17). By con-
trast, effects of CRTC2AA on gluconeogenic gene expression
were more modest, likely reflecting in part compensatory
increases in the AKT-mediated phosphorylation and inactiva-
tion of the forkhead transcription factor FOXO1 (Fig. 2).
Hepatic expression of activated CRTC2 had no appreciable
effect in other tissues, indicating that CREB/CRTC2 signaling
primarily modulates hepatic insulin resistance.
Studies with STZ diabetic mice support an important role
for insulin in attenuating CREB/CRTC activity during feed-
ing. CRTC2 occupancy over gluconeogenic genes was
increased in STZ diabetic mice primarily during feeding,
when CRTC2 activity is otherwise down-regulated in
response to insulin (21).
The chronic increases in CRTC2 activity and in gluconeo-
genic gene expression led to persistent elevations in fasting as
FIGURE 4. Chronic activation of the CREB pathway in liver increases fasting blood glucose concentrations. a, average overnight fasting blood glucose
levels ofmice infectedwithAAV.Empty or AAV.CRTC2AAover a 37-day period,n 10. b, averagebloodglucose levels during ad-lib and fasting conditions; day
17–30,n10–20. c, pyruvate tolerance test onday20post virus injection, 2 g sodiumpyruvate/kgmouse,n7. Right hand sideof the figure shows calculated
total area under the curve and incremental area under the curve. d, intraperitoneal glucose tolerance test on day 10 following viral infection, 1 g glucose/kg
mouse, n 10. Right, calculated total and incremental area under the curve. e, continuous glucose monitoring over a 24 h light/dark cycle with free access to
food andwater; n 2 per group, 2 days ofmonitoring; average values shown. (*, p 0.05; **, p 0.005; ***, p 0.0005 comparedwith AAV.Emptymice; data
shown as mean S.E.).
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well as ad libitum fed blood glucose levels. These observations
indicate that the increase in gluconeogenesis is not suppressible
and thus the baseline blood glucose of these animals has been
“reset” to a higher level. Indeed, in continuous glucose moni-
toring studies, AAV.CRTC2AA mice had elevated blood glu-
cose concentrations throughout the day/night cycle. As a result,
mice expressing CRTC2AA are more insulin resistant due in
part to the increase in hepatic gluconeogenesis. No direct mea-
sure of insulin resistance in liver was performed in our study,
however; future work should confirm the apparent effects of
CRTC2AA on hepatic glucose output.
Despite the presence of hepatic insulin resistance, the insulin
response to the glucose challenge is appropriate to dispose of
the glucose load at the same rate as in the control mice. This
increase in the insulin response is consistent with the increase
in -cell area observed, which appears to be secondary to the
hepatic insulin resistance.
The increase in islet area in AAV.CRTC2AA mice, which
occurs due to hyperplasia rather than hypertrophy, appears to
be limited to  cells and likely includes an increase in -cell
proliferation. Several mechanisms could underlie the expan-
sion of -cells in this setting. First, -cell replication can be
FIGURE 5. Expression of phosphorylation-defective CRTC2 increases hepatic insulin resistance and steatosis. a, insulin tolerance test on day 7 after viral
infection, 1 unit insulin/kg mouse, n 8. Right, calculated inverse area under the curve. b, epididymal WAT (left) and quad muscles (right) tissues probed for
phospho- and totalAKT10minpost IP injectionof salineor insulin (1unit/kgmouse).Quantification is shownbelow theblots. c, H&E sectionsof livers frommice
on day 14 and 36 post viral infection. d, liver triglycerides, day 36 post viral injection, standardized tomg total protein, n 5. (*, p 0.05; **, p 0.005; ***, p
0.0005 compared with AAV.Empty mice; data shown as mean S.E.).
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driven by increased secretory demand placed upon the islet by
dietary-fat-induced obesity and insulin resistance or chronic,
mild hyperglycemia (24, 25). Additionally, secreted factors such
as hepatocyte growth factor or glucagon-like peptide-1 can
induce -cell replication (26–28). It is also possible that the
constitutively active expression of CRTC2 in the liver promotes
transcription of a liver derived factor, which then promotes
-cell hyperplasia, such as that described by El Ouaamari et al.
in 2013 (29). Future studies should provide insight into this
process.
We found that a persistent increase in CREB activity for a
period of 5 weeks is sufficient to produce hepatic insulin resis-
tance, leading to fasting hyperglycemia. Our studies also reveal
that hepatic CREB signaling determines the homeostatic set
point for plasma glucose concentrations. This persistent hyper-
glycemia was associated with a compensatory increase in -cell
area and an elevation of circulating insulin levels, thus prevent-
ing dramatic increases in fasting and post-prandial glucose.
Future studies should reveal whether increases in circulating
insulin concentrations promote fat accumulation in the liver,
which is associated with insulin resistance (30–34).
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